Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis

Inclusion Criteria:

* Histologically proven oligodendroglioma or anaplastic oligoastrocytoma, newly diagnosed, resulting or not from a low grade glioma
* Tumor with measurable contrast enhancement (at least 15 mm in diameter)
* Surgical procedure limited to a biopsy or partial excision
* In the event of partial excision, an early postoperative check-up (\<72 hours) performed at best by MRI, if not by CT, is required.
* Time between surgery and inclusion less than or equal to one and a half months (45 days)
* Age\> 18 years old; \<70
* Karnofsky index\> 60
* Stable or reduced dose of corticosteroids in the 15 days prior to inclusion
* Polynuclear neutrophils\> 1500; platelets\> 100,000
* Bilirubin \<1.25 x UNL; SGOT, SGPT, PAL \<2.5 x UNL
* Absence of serious uncontrolled pathology
* Patient having received and understood the information and having signed the consent

Exclusion Criteria:

* Presence of GBM foci within the tumor
* Absence of evaluable residue after surgery
* Previous chemotherapy or radiotherapy
* Unsatisfactory expected monitoring conditions
* Pregnant or breastfeeding woman; lack of effective contraception if of childbearing age
* History of malignant disease (with the exception of CIS of the cervix and basal cell cancer)
* Contraindications related to the examination of the I.R.M.